The onconeuronal cerebellar degeneration-related antigen Cdr2 is associated with paraneoplastic syndromes. Neoplastic expression of Cdr2 in ovary and breast tumors triggers an autoimmune response that suppresses tumor growth by developing tumor immunity, but culminates in cerebellar degeneration when Cdr2-specific immune cells recognize neuronal Cdr2. We identified Cdr2 as novel interactor of the hypoxia-inducible factor (HIF) prolyl-4-hydroxylase PHD1 and provide evidence that Cdr2 might represent a novel important tumor antigen in renal cancer. Strong Cdr2 protein expression was observed in 54.2% of papillary renal cell carcinoma (RCC) compared to 7.8% of clear cell RCC and no staining in chromophobe RCC or oncocytoma. High Cdr2 protein levels correlated with strongly attenuated HIF target gene expression in these solid tumors and Cdr2 overexpression in tumor cell lines reduced HIF-dependent transcriptional regulation. This effect was due to both attenuation of hypoxic protein accumulation and suppression of the transactivation activity of HIF-1a. Papillary (p)RCC is known for its tendency to avascularity, usually associated with a lower pathological stage and higher survival rates. We provide evidence that Cdr2 protein strongly accumulates in pRCC, attenuates the HIF response to tumor hypoxia and may become of diagnostic importance as novel renal tumor marker.